Log In
person
Sandoz Group AG
SDZNY
summarize
2 total product lines
calendar_month
Revenue as of 12/31/2023
| Reporting Segmentarrow_drop_up | Product Line | Amount (USD) | Percentage |
|---|---|---|---|
| keyboard_arrow_right | Reporting Segment & Product Line | Amount (USD) | Percentage |
| Off-Patent Medicines |
Generic Pharmaceuticals
These companies manufacture generic drugs.
|
7.43B | 77.04% |
| Off-Patent Medicines |
Biosimilars; sold through distributor
These companies research, develop, and manufacture biosimilars, or biopharmaceutical products that are marketed as an alternative to other companies' products.
|
2.22B | 22.96% |
| keyboard_arrow_down |
Off-Patent Medicines
Generic Pharmaceuticals
|
7.43B | 77.04% |
| keyboard_arrow_right |
These companies manufacture generic drugs.
|
||
| keyboard_arrow_down |
Off-Patent Medicines
Biosimilars; sold through distributor
|
2.22B | 22.96% |
| keyboard_arrow_right |
These companies research, develop, and manufacture biosimilars, or biopharmaceutical products that are marketed as an alternative to other companies' products.
|
||